Dolutegravir-Based ART Regimens May Be Appropriate Second-Line Therapy In Patients With HIV, Study Finds

Infectious Disease Advisor (8/11, Nye) reports a study found that “in the setting of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy (ART), dolutegravir (DTG)-based ART regimens may be an appropriate option for second-line therapy in patients with HIV infection.” Researchers observed that “the rate of virologic suppression at 96 weeks was 76.1% in patients who received DRV/r+2NRTIs, 85.7% in those who received DTG+DRV/r, and 81.6% in those who received DTG+TDF/XTC. Compared with patients who received DRV/r+2NRTIs, the rate of virologic suppression was significantly higher in those who received DTG+DRV/r and those who received DTG+TDF/XTC.” The study was published in Clinical Infectious Diseases.